



WEST MICHIGAN CANCER CENTER

Passionate Science. Compassionate Care.

7 September 2010

Colleen Carol Casey
Materials Licensing Section
U.S. Nuclear Regulatory Commission, Region III
2443 Warrenville Rd.
Lisle, IL 60532-4352

Subject: Amendment requests for license number 21-32501-01

This is a request of The West Michigan Cancer Center for the following amendment to its materials license no. 21-32501-01.

Request to add Dr. Jacquelyn Watson as an authorized user for Iridium-192 in a remote after-loading brachytherapy device permitted by 10CFR 35.600. Dr. Watson was an authorized user for Iridium-192 on NRC License Number 21-00243-06. A copy of this license is attached.

If there are any questions, please do not hesitate to contact me at (269) 373-7407.
Thank you.

Paul Jursinic, Ph.D.
Radiation Safety Officer
West Michigan Cancer Center

INSTITUTE
PUBLICATION
DEPARTMENT
P 269.382.2500

KALAMAZOO
COMMUNITY
CLINICAL
ONCOLOGY
P 269.373.7450

MICHIGAN
ONCOLOGY
P 269.382.2500

NEURO-
ONCOLOGY
P 269.382.2500

RADIATION
ONCOLOGY
P 269.382.2500

GENERAL
P 269.382.2500



Official Use Only - Security-Related Information

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 8 PAGES

Amendment No. 64

MATERIALS LICENSE

Corrected Copy

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		In accordance with letters dated August 28, 2006, and October 2, 2006,
1. Spectrum Health Hospitals		3. License number 21-00243-06 is amended in its entirety to read as follows:
2. 100 Michigan N.E. Grand Rapids, MI 49503		4. Expiration date December 31, 2011
		5. Docket No. 030-01989 Reference No. 10
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed 1 curie of iodine-131)
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed sources	D. Ten curies
E. Any byproduct material permitted by 10 CFR 35.500	E. Sealed sources	E. One curie
F. Any byproduct material identified in 10 CFR 31.11	F. Prepackaged kits	F. As needed
G. Uranium depleted in Uranium-235	G. Cadmium plated metal	G. As needed

Official Use Only - Security-Related Information



Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 8 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-00243-06

Docket or Reference Number
030-01989

Amendment No. 64

Corrected Copy

Kenneth J. Gritter, M.D. 10 CFR 35.100, 35.200, 35.300 and 35.500.

~ Jacquelyn Watson, M.D. 10 CFR 35.400 and iridium-192 in HDR remote afterloading brachytherapy device.

Steven Waslowski, M.D. 10 CFR 35.100, 35.200, 35.500.

Bradford W. Betz, M.D. 10 CFR 35.100, 35.200, 35.300 and 35.500.

Thomas J. Monroe, Ph.D. Subitem Nos. 6.H., 6.I., and 6.J.

Eric Buth, M.D. 10 CFR 35.400 and iridium-192 in HDR remote afterloading brachytherapy device.

Michael Mahacek, M.D. 10 CFR 35.400 and iridium-192 in HDR remote afterloading brachytherapy device.

Thomas A. Getz, M.D. 10 CFR 35.100, 35.200 and 35.300, limited to therapy procedures for which the patient can be released under the provisions of 10 CFR 35.75.

Armand Michael LaSorsa, M.D. 10 CFR 35.100, 35.200, 35.300 and 35.500.

William W. Laidlaw, M.D. 10 CFR 35.100, 35.200, and 35.500.

Henry Van Derkolk, M.D. 10 CFR 35.100, 35.200, 35.300 and 35.500.

John W. Quick, M.D. 10 CFR 35.100, 35.200, and 35.500.

Brian Fedeson, M.D. 10 CFR 35.100, 35.200, and 35.500.

Neil Peterson, M.D. 10 CFR 35.100, 35.200, and 35.500.

Jeffrey A. Chestnut, D.O. 10 CFR 35.100, 35.200, 35.300 and 35.500.

Craig Moore, M.D. 10 CFR 35.100, 35.200, 35.300 and 35.500.

Gregory L. Miller, M.D. 10 CFR 35.200 and 35.500.

William LaPenna, M.D. 10 CFR 35.200 and 35.500.

Official Use Only - Security-Related Information

P. JORSWIC



West Michigan Cancer Center
Together, we win.

RESORTED
FIRST CLASS



02 1M/
0004265740

\$ 00.38²
SEP07 2010

MAILED FROM ZIP CODE 49009

PRSR 1STCLASS 09/07/10



Colleen Carol Casey
Materials Licensing Section
U.S. Nuclear Regulatory Commission, Region III
2443 Warrenville Rd.
Lisle, IL 60532-4352

CCXHPM1 60532

